Search
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc. … (NV).
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigational[L45295] Velmanase alfa is currently not approved in Canada. … [L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigationalTafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal. … [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Oseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalThe authors concluded that oseltamivir use in healthy adults had small, non-specific effects on symptoms (where the time to first alleviation of symptoms was only reduced from 7 to 6.3 days), it had no … effect on hospitalizations, and that there was no evidence for any reductions in complications of influenza such as pneumonia.
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalThis drug was developed by Chiasma Inc.[L14495,L14507,L14528] … [L14513] In the past, octreotide has been administered solely by injection.
Finasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigational[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalAn oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia.
Pivmecillinam
go.drugbank.com/drugs/DB01605ApprovedInvestigationalPivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.
Choline
go.drugbank.com/drugs/DB00122ApprovedInvestigationalNutraceuticalA basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
Synonyms: N,N,N-trimethylethanol-ammonium, N-trimethylethanolamineMixtures: Super Daily No 2, Doctor's Choice Brand for Men